Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its wholly-owned subsidiary, SystImmune, recently received a $250 million milestone payment from Bristol-Myers Squibb (BMY). According to the collaboration agreement, the company is also eligible for up to an additional $250 million in near-term contingent payments, as well as potential payments of up to $7.1 billion upon achieving specific development, regulatory, and sales milestones. The milestone payments outlined in the agreement are subject to certain conditions, and the final payment amounts remain uncertain.